Targeting CXCR4-induced Desmoplasia to Improve Checkpoint Inhibition in Breast Cancer

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2019 Feb 24

PMID 30796186

Citations 5

Authors

George W Sledge

Affiliations

Soon will be listed here.

Citing Articles

Fibroblasts as Turned Agents in Cancer Progression.

Wieder R Cancers (Basel). 2023; 15(7).

PMID: 37046676 PMC: 10093070. DOI: 10.3390/cancers15072014.

The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma.

Wu X, Zhang H, Sui Z, Wang Y, Yu Z Cancer Biol Med. 2021; .

PMID: 33710803 PMC: 8185864. DOI: 10.20892/j.issn.2095-3941.2020.0140.

The Roles of Stroma-Derived Chemokine in Different Stages of Cancer Metastases.

Hussain S, Peng B, Cherian M, Song J, Ahirwar D, Ganju R Front Immunol. 2021; 11:598532.

PMID: 33414786 PMC: 7783453. DOI: 10.3389/fimmu.2020.598532.

Increased Survival by Pulmonary Treatment of Established Lung Metastases with Dual STAT3/CXCR4 Inhibition by siRNA Nanoemulsions.

Li Z, Chen G, Ding L, Wang Y, Zhu C, Wang K Mol Ther. 2019; 27(12):2100-2110.

PMID: 31481310 PMC: 6904825. DOI: 10.1016/j.ymthe.2019.08.008.

Targeting cancer stem cells in drug discovery: Current state and future perspectives.

Du F, Zhou Q, Sun W, Chen G World J Stem Cells. 2019; 11(7):398-420.

PMID: 31396368 PMC: 6682504. DOI: 10.4252/wjsc.v11.i7.398.

References

Hasebe T, Imoto S, Yokose T, Ishii G, Iwasaki M, Wada N . Histopathologic factors significantly associated with initial organ-specific metastasis by invasive ductal carcinoma of the breast: a prospective study. Hum Pathol. 2008; 39(5):681-93. DOI: 10.1016/j.humpath.2007.09.012. View

Mujtaba S, Ni Y, Tsang J, Chan S, Yamaguchi R, Tanaka M . Fibrotic focus in breast carcinomas: relationship with prognostic parameters and biomarkers. Ann Surg Oncol. 2013; 20(9):2842-9. DOI: 10.1245/s10434-013-2955-0. View

Jiang H, Hegde S, DeNardo D . Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol Immunother. 2017; 66(8):1037-1048. PMC: 5603233. DOI: 10.1007/s00262-017-2003-1. View

Pernas S, Martin M, Kaufman P, Gil-Martin M, Pardo P, Lopez-Tarruella S . Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol. 2018; 19(6):812-824. DOI: 10.1016/S1470-2045(18)30147-5. View

Brooks D, Zimmer A, Wakefield L, Lyle L, Difilippantonio S, Tucci F . Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget. 2018; 9(34):23462-23481. PMC: 5955109. DOI: 10.18632/oncotarget.25231. View